Multisystemic inflammation and fulminant myocarditis: what the evidence says about non-COVID causes

Most people, when they hear "heart inflammation," picture a complication of COVID-19 or a rare side effect of a vaccine. The reality is messier and more important than that. Myocarditis -- inflammation of the heart muscle -- has been with us for decades, driven by a long list of viruses, autoimmune processes, and medications that have nothing to do with SARS-CoV-2. And when that inflammation turns fulminant, meaning it escalates rapidly into life-threatening cardiac dysfunction, the clinical picture often involves the entire body, not just the heart.

A study indexed on PubMed in 2025 examined the characteristics and outcomes of multisystemic inflammation specifically in patients with non-COVID-19-related fulminant myocarditis (https://pubmed.ncbi.nlm.nih.gov/42273305/). The findings are a useful reminder that severe myocarditis is not a post-pandemic curiosity -- it is an ongoing clinical challenge that benefits from early recognition, a thorough workup, and a clinician who knows your baseline.

At NoMi Beach Health, Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) sees this pattern as a core reason why longitudinal, relationship-based primary care matters. When something shifts in your body, the clinician who already knows what "normal" looks like for you is the one most likely to catch it early.

What fulminant myocarditis actually is

Myocarditis is inflammation of the myocardium -- the muscular wall of the heart. In most cases, it is mild, self-limiting, and resolves with rest and supportive care. Fulminant myocarditis is the exception. It is characterized by an abrupt onset, rapid hemodynamic compromise, and a high risk of short-term mortality without aggressive intervention (Cooper LT Jr., N Engl J Med, 2009; https://doi.org/10.1056/NEJMra0800028).

The word "fulminant" comes from the Latin for "lightning." That is an accurate description. A person can go from feeling a little off after what seemed like a routine viral illness to requiring mechanical circulatory support within 24 to 72 hours. Left ventricular function can drop dramatically in that window. Arrhythmias can emerge without warning.

What makes the 2025 PubMed study noteworthy is its focus on the multisystemic dimension. In fulminant presentations, the inflammation does not stay neatly inside the heart. Liver enzymes climb. Kidney function falters. Ferritin, CRP, and other inflammatory markers spike. This pattern -- widespread systemic involvement alongside cardiac dysfunction -- appears to be a distinguishing feature of the most severe non-COVID cases and has implications for how aggressively clinicians should respond when they see it.

The non-COVID triggers clinicians look for

Before COVID-19 dominated the myocarditis conversation, the textbook causes were well-established. Enteroviruses, particularly coxsackievirus B, have historically been the most commonly implicated viral agents in Western populations (Kindermann I, et al., J Am Coll Cardiol, 2012; https://doi.org/10.1016/j.jacc.2011.09.074). Herpesviruses -- including cytomegalovirus and Epstein-Barr virus -- also appear on the list, as do adenoviruses and parvovirus B19.

Beyond viruses, autoimmune conditions deserve serious attention. Giant cell myocarditis, an autoimmune-driven form, carries a particularly grim prognosis without immunosuppression (Frustaci A, et al., Circulation, 2003; https://doi.org/10.1161/01.CIR.0000048147.15962.31). Sarcoidosis and systemic lupus erythematosus can both involve the myocardium. Certain medications -- immune checkpoint inhibitors used in cancer treatment, clozapine, and some antibiotics -- are recognized cardiotoxic agents.

The clinical implication is straightforward: when a patient presents with new cardiac symptoms and a recent viral-sounding illness, the differential is wide. Assuming the cause is known without a workup is a shortcut that can cost a life.

How myocarditis is diagnosed -- and where clinicians can miss it

Myocarditis is famously easy to miss because its early symptoms overlap with a dozen more common problems. Chest pain can look like musculoskeletal pain or costochondritis. Fatigue after a viral illness is expected. Mild shortness of breath is easy to attribute to deconditioning.

The European Society of Cardiology's position statement on myocarditis outlines a stepwise diagnostic approach that starts with clinical suspicion and then layers in objective data (Caforio ALP, et al., Eur Heart J, 2013; https://doi.org/10.1093/eurheartj/eht210). An ECG may show diffuse ST changes, new-onset bundle branch block, or arrhythmia. Troponin -- the blood marker of heart muscle injury -- is elevated in most clinically significant cases. BNP or NT-proBNP reflects the degree of ventricular stress.

Echocardiography gives a real-time picture of ventricular function, wall motion, and pericardial involvement. Cardiac MRI, when available, is now considered the gold standard for non-invasive tissue characterization, capable of identifying myocardial edema, hyperemia, and fibrosis with high sensitivity and specificity (Ferreira VM, et al., J Am Coll Cardiol, 2018; https://doi.org/10.1016/j.jacc.2018.09.072).

Endomyocardial biopsy -- a catheter-based procedure to sample heart tissue -- remains the definitive diagnostic tool, but it is reserved for cases where the diagnosis is uncertain and the stakes are high. The Dallas criteria for histologic diagnosis have been largely superseded by immunohistochemical and molecular techniques, though the biopsy itself remains valuable in severe or treatment-refractory presentations (Baughman KL, Circulation, 2006; https://doi.org/10.1161/CIRCULATIONAHA.105.589663).

In the fulminant setting, speed matters more than diagnostic elegance. What clinicians look for is a cluster of signs -- rapid hemodynamic deterioration, elevated inflammatory markers, multiorgan involvement, and new cardiac dysfunction in the absence of obstructive coronary disease -- that together push the probability high enough to act.

What multisystemic inflammation tells us about severity

The reason the 2025 study on non-COVID fulminant myocarditis is clinically useful is precisely its attention to what happens outside the heart. When inflammation becomes systemic -- elevated hepatic enzymes, rising creatinine, hyperferritinemia, and cytokine-driven temperature dysregulation -- the picture begins to resemble cytokine release syndrome, a pattern familiar from severe COVID-19 and certain autoimmune emergencies.

In the study population, patients with broader multisystemic involvement tended to have more severe presentations and, in some analyses, different outcomes than those with more isolated cardiac findings. The exact prognostic weight of each systemic marker is still being worked out, but the clinical message is clear: if you see the heart and the liver and the kidneys moving in the wrong direction at the same time, you are not dealing with a routine viral myocarditis. You are dealing with something that needs intensive-level attention and a multidisciplinary team.

For the concierge primary care setting, this is a referral and recognition problem more than a treatment problem. We are not the intensive care unit. What we are is the clinician who knows that your ferritin was normal at your last annual physical, that your ECG baseline was unremarkable, and that the fatigue you are describing now is different from your usual pattern. That baseline knowledge -- the kind you build over years of longitudinal care -- is what makes early recognition possible. We cover what a thorough annual visit looks like in our complete guide to concierge primary care, and it is directly relevant here.

Treatment principles -- what the evidence supports

For hemodynamically stable patients with suspected viral myocarditis, supportive care is the foundation: rest, guideline-directed heart failure therapy if the ejection fraction is reduced, and close monitoring. NSAIDs are generally avoided in the acute phase because of potential adverse cardiac remodeling effects.

For fulminant cases with rapid deterioration, mechanical circulatory support -- intra-aortic balloon pump, Impella, or extracorporeal membrane oxygenation (ECMO) -- can bridge patients through the most dangerous window while the myocardium recovers. The potential for recovery with adequate support is actually one of the more encouraging features of fulminant myocarditis compared to its non-fulminant counterpart; those who survive the acute phase often recover substantial ventricular function (Ammirati E, et al., J Am Coll Cardiol, 2019; https://doi.org/10.1016/j.jacc.2019.04.063).

When an autoimmune etiology is confirmed or strongly suspected -- giant cell myocarditis, cardiac sarcoidosis, or myocarditis associated with immune checkpoint inhibitors -- immunosuppressive therapy becomes a central part of management. High-dose corticosteroids are the typical starting point; additional agents depend on the specific diagnosis and response.

The treatment of myocarditis tied to immune checkpoint inhibitors used in cancer care is an emerging area with rapidly accumulating evidence. These drugs have transformed oncology, but immune-related adverse events -- including severe myocarditis -- are a recognized and sometimes fatal complication (Bozkurt B, et al., Circulation, 2021; https://doi.org/10.1161/CIRCULATIONAHA.121.056135). If you are on a checkpoint inhibitor and develop new cardiac symptoms, that is an urgent cardiology referral, not a watchful-waiting situation.

What recovery looks like and why follow-up matters

Surviving fulminant myocarditis is not the end of the story. Even patients who recover substantial cardiac function need structured follow-up. Repeat cardiac imaging -- typically at three to six months and then annually or as clinically indicated -- tracks ventricular recovery and screens for late fibrosis, which can serve as a substrate for arrhythmia.

Exercise restriction during recovery is standard practice across society guidelines, typically for three to six months after the acute phase, with return to activity guided by imaging and symptom response. Competitive athletes require especially careful clearance given the arrhythmia risk associated with exercise during active myocardial inflammation.

The systemic triggers identified during the acute workup also need follow-through. If an autoimmune condition drove the myocarditis, that condition needs ongoing management. If a medication was implicated, that agent is typically discontinued permanently. If a viral trigger was identified, surveillance for recurrence is appropriate in certain high-risk populations.

This is where our primary care model fits into the longer arc. Post-myocarditis surveillance is not a one-and-done cardiology visit. It is a sustained relationship between a patient and a clinician who tracks the full picture over time -- labs, symptoms, medication list, lifestyle factors -- and who coordinates specialist input when it is needed. If you have been through myocarditis, or you are worried about the symptoms described in this post, that longitudinal relationship is worth building before the next emergency, not after it.

The bigger picture -- inflammation as a system problem

Fulminant myocarditis is, in a sense, a concentrated and dramatic expression of something that matters across a much wider range of clinical situations: unchecked systemic inflammation causes organ damage, and the heart is rarely the only organ at risk.

The inflammatory mechanisms at play in myocarditis share features with those implicated in conditions we address regularly in primary care -- cardiovascular risk driven by chronic low-grade inflammation, metabolic dysfunction, and the downstream effects of untreated chronic illness. Understanding inflammation as a system-level phenomenon rather than a single-organ problem is part of how integrative, evidence-grounded primary care adds value that episodic, problem-focused care cannot.

That does not mean every tired patient has myocarditis. It means the clinician who is paying attention to patterns, running the right baseline labs, and maintaining a longitudinal relationship with you is the one who will notice when something does not fit -- and act on it early enough to matter.

---

If you have had a recent viral illness followed by chest discomfort, unexplained palpitations, or fatigue that feels different from your baseline -- or if you want a primary care clinician who keeps track of your cardiovascular and inflammatory markers over time -- book a visit with us at NoMi Beach Health or call (786) 744-5152. Dr. Harris will look at your full picture, not just the problem in front of you.